exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088007 RNA Name: hsa-miR-302c-3p RNA Type: miRNA Chromosome: chr4 Starnd: - Coordinate: Start Site(bp): 112648366 End Site(bp): 112648388 External Links: hsa-miR-302c-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MTMR12 chr5 32226994 32312987 - TXNIP chr1 145992435 145996579 - CLU chr8 27596917 27614700 - MBP chr18 76978827 77133683 - CCNB1 chr5 69167135 69178245 + SETD7 chr4 139495941 139606699 - NUP153 chr6 17615035 17706834 - SEC16A chr9 136440096 136483759 - SLAIN2 chr4 48341529 48426201 + ZSCAN26 chr6 28267010 28278224 + CUL1 chr7 148697914 148801110 + TRA2A chr7 23504780 23532041 - TEFM chr17 30897336 30906238 - CCNG2 chr4 77157207 77433388 + CDK6 chr7 92604921 92836594 - FYCO1 chr3 45917899 45995824 - PSMD5 chr9 120815496 120842951 - MTFR2 chr6 136231024 136250335 - VRK1 chr14 96797382 96931722 + UGP2 chr2 63840940 63891562 + KMT5B chr11 68154863 68213828 - SEMA3C chr7 80742538 80922359 - COX7C chr5 86617928 86620962 + SRRT chr7 100875103 100888664 + BCL7A chr12 122019422 122062044 + PDXK chr21 43719094 43762307 + MOB1A chr2 74152528 74178898 - MSTO1 chr1 155610188 155614971 + NPC2 chr14 74476192 74494177 - CAMK2N1 chr1 20482391 20486210 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC011503.2 chr19 23927788 23929287 + AC125257.1 chr17 41848518 41851447 - AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.